Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03862469
Other study ID # 2018-1533
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 26, 2019
Est. completion date September 1, 2023

Study information

Verified date February 2024
Source University of Illinois at Chicago
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PHASE is designed to evaluate neuroactive hormone trajectories across the menstrual cycle and endocrine, autonomic, and subjective responses to psychosocial stress in women suffering from severe PMS (i.e., premenstrual dysphoric disorder).


Description:

Female volunteers will be recruited from the community for participation in this 3-menstrual cycle study. In the first two menstrual cycles, study participants will chart their symptoms and and ovulation. Study participants will continue to perform ovulation testing during their third menstrual cycle in which they will attend one individualized task session and provide 8 serum samples at different timepoints across the menstrual cycle. Primary analyses will contrast neuroactive hormone trajectories across the menstrual cycle and stress reactivity according to study groups (PMDD vs healthy).


Recruitment information / eligibility

Status Completed
Enrollment 207
Est. completion date September 1, 2023
Est. primary completion date September 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Female - Aged 18-35 years, established by visual inspection of a government-issued ID - Average menstrual cycle 21-35 days Exclusion Criteria: - Lifetime DSM-5 Axis 1 disorder (except anxiety and depression), as documented in the Mental Health Interview - Current DSM-5 Axis depressive or anxiety disorder, as documented in the Mental Health Interview - Positive urine drug screen test - Breath alcohol concentration >0.00% - Self-reported smoker or carbon monoxide concentration = 6 ppm - Irregular menstrual cycle - Current pregnancy (urine test-verified) or lactation, or a plan to become pregnant - Moderate or high suicide risk - Shipley IQ (vocabulary standard score) > 80 - Any prescription medications (including hormonal forms of birth control)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Individualized laboratory test
Laboratory test administered between 6 and 2 days prior to the subsequent menstrual cycle.

Locations

Country Name City State
United States University of Illinois Department of Pharmacy Practice Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
University of Illinois at Chicago

Country where clinical trial is conducted

United States, 

References & Publications (25)

Allen AP, Kennedy PJ, Dockray S, Cryan JF, Dinan TG, Clarke G. The Trier Social Stress Test: Principles and practice. Neurobiol Stress. 2016 Nov 12;6:113-126. doi: 10.1016/j.ynstr.2016.11.001. eCollection 2017 Feb. — View Citation

American College of Obstetricians and Gynecologists. Premenstrual Syndrome. ACOG Practice Bulletin No. 15. Washington, DC: American College of Obstetricians and Gynecologists, 2000.

Backstrom T, Sanders D, Leask R, Davidson D, Warner P, Bancroft J. Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom Med. 1983 Dec;45(6):503-7. doi: 10.1097/00006842-198312000-00004. — View Citation

Carlin, J. B., Galati, J. C., & Royston, P. (2008). A new framework for managing and analyzing multiply imputed data in Stata. Stata Journal, 8(1), 49-67.

Critchlow DG, Bond AJ, Wingrove J. Mood disorder history and personality assessment in premenstrual dysphoric disorder. J Clin Psychiatry. 2001 Sep;62(9):688-93. doi: 10.4088/jcp.v62n0905. — View Citation

Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009;17(2):120-37. doi: 10.1080/10673220902891836. — View Citation

Deng D, Pang Y, Duan G, Liu H, Liao H, Liu P, Liu Y, Li S, Chen W, Wen D, Xuan C, Li M. Larger volume and different functional connectivity of the amygdala in women with premenstrual syndrome. Eur Radiol. 2018 May;28(5):1900-1908. doi: 10.1007/s00330-017-5206-0. Epub 2017 Dec 19. — View Citation

Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006 Jan;9(1):41-9. doi: 10.1007/s00737-005-0103-y. Epub 2005 Sep 20. — View Citation

Fischer S, Cleare AJ. Cortisol as a predictor of psychological therapy response in anxiety disorders-Systematic review and meta-analysis. J Anxiety Disord. 2017 Apr;47:60-68. doi: 10.1016/j.janxdis.2017.02.007. Epub 2017 Feb 24. — View Citation

Hamidovic A, Childs E, Conrad M, King A, de Wit H. Stress-induced changes in mood and cortisol release predict mood effects of amphetamine. Drug Alcohol Depend. 2010 Jun 1;109(1-3):175-80. doi: 10.1016/j.drugalcdep.2009.12.029. Epub 2010 Feb 21. — View Citation

Howards PP, Schisterman EF, Wactawski-Wende J, Reschke JE, Frazer AA, Hovey KM. Timing clinic visits to phases of the menstrual cycle by using a fertility monitor: the BioCycle Study. Am J Epidemiol. 2009 Jan 1;169(1):105-12. doi: 10.1093/aje/kwn287. Epub 2008 Oct 30. — View Citation

Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993;28(1-2):76-81. doi: 10.1159/000119004. — View Citation

Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry. 2006 May;63(5):484-9. doi: 10.1001/archpsyc.63.5.484. — View Citation

Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011 May;45(5):626-9. doi: 10.1016/j.jpsychires.2010.10.008. Epub 2010 Oct 28. — View Citation

Lovick TA. Estrous cycle and stress: influence of progesterone on the female brain. Braz J Med Biol Res. 2012 Apr;45(4):314-20. doi: 10.1590/s0100-879x2012007500044. Epub 2012 Mar 29. — View Citation

Moore CG, Carter RE, Nietert PJ, Stewart PW. Recommendations for planning pilot studies in clinical and translational research. Clin Transl Sci. 2011 Oct;4(5):332-7. doi: 10.1111/j.1752-8062.2011.00347.x. — View Citation

Qiao M, Zhang H, Liu H, Luo S, Wang T, Zhang J, Ji L. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample in China. Eur J Obstet Gynecol Reprod Biol. 2012 May;162(1):83-6. doi: 10.1016/j.ejogrb.2012.01.017. Epub 2012 Feb 28. — View Citation

Rubinow DR, Schmidt PJ. Gonadal steroid regulation of mood: the lessons of premenstrual syndrome. Front Neuroendocrinol. 2006 Jul;27(2):210-6. doi: 10.1016/j.yfrne.2006.02.003. Epub 2006 May 2. — View Citation

Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998 Jan 22;338(4):209-16. doi: 10.1056/NEJM199801223380401. — View Citation

Sohda S, Suzuki K, Igari I. Relationship Between the Menstrual Cycle and Timing of Ovulation Revealed by New Protocols: Analysis of Data from a Self-Tracking Health App. J Med Internet Res. 2017 Nov 27;19(11):e391. doi: 10.2196/jmir.7468. — View Citation

Solis-Ortiz S, Corsi-Cabrera M. Sustained attention is favored by progesterone during early luteal phase and visuo-spatial memory by estrogens during ovulatory phase in young women. Psychoneuroendocrinology. 2008 Aug;33(7):989-98. doi: 10.1016/j.psyneuen.2008.04.003. Epub 2008 Jul 21. — View Citation

Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, Robson R, Thabane M, Giangregorio L, Goldsmith CH. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010 Jan 6;10:1. doi: 10.1186/1471-2288-10-1. Erratum In: BMC Med Res Methodol. 2023 Mar 11;23(1):59. — View Citation

Toffol E, Heikinheimo O, Partonen T. Associations between psychological well-being, mental health, and hormone therapy in perimenopausal and postmenopausal women: results of two population-based studies. Menopause. 2013 Jun;20(6):667-76. doi: 10.1097/gme.0b013e318278eec1. — View Citation

Whooley MA, Grady D, Cauley JA. Postmenopausal estrogen therapy and depressive symptoms in older women. J Gen Intern Med. 2000 Aug;15(8):535-41. doi: 10.1046/j.1525-1497.2000.04029.x. — View Citation

Yen JY, Wang PW, Su CH, Liu TL, Long CY, Ko CH. Estrogen levels, emotion regulation, and emotional symptoms of women with premenstrual dysphoric disorder: The moderating effect of estrogen receptor 1alpha polymorphism. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:216-223. doi: 10.1016/j.pnpbp.2017.11.013. Epub 2017 Nov 14. — View Citation

* Note: There are 25 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Hormone Analysis Allopregnanolone, cortisol, progesterone 2 hours
Primary Cardiovascular function Heart Rate, Heart Rate Variability 2 hours
Primary Affect Subjective Mood States 2 hours
Primary Estradiol concentrations at 6 menstrual cycle sub-phases Mean levels of estradiol One menstrual cycle
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00536198 - Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder N/A
Completed NCT03449979 - Single Session of tACS in a Depressive Episode N/A
Completed NCT00516113 - A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria Phase 4
Recruiting NCT05098574 - Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder Phase 2
Withdrawn NCT04123483 - EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders Phase 4
Completed NCT00518570 - Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD) N/A
Not yet recruiting NCT01217775 - Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder Phase 3
Terminated NCT02362191 - Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD N/A
Completed NCT00678574 - The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder Phase 4
Active, not recruiting NCT05327075 - Premenstrual Dysphoric Disorder:Knowledge,Attitude and Practice Among Egyptian Females
Not yet recruiting NCT02448836 - Deep Transcranial Magnetic Stimulation (dTMS) for the Treatment of Premenstrual Dysphoric Disorder (PMDD) N/A
Completed NCT01799733 - Alternative Treatments for Premenstrual Dysphoric Disorder N/A
Completed NCT06227676 - Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25 Phase 2/Phase 3
Active, not recruiting NCT02508103 - Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study Phase 2/Phase 3
Completed NCT00927095 - Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD) Phase 4
Completed NCT00089414 - Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives Phase 2
Not yet recruiting NCT06462391 - Adapting and Piloting Acceptance and Commitment Therapy (ACT) for Severe Premenstrual Mood Symptoms N/A
Completed NCT01875718 - A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD) Phase 1/Phase 2
Completed NCT06136104 - The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms N/A
Completed NCT01385709 - The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels N/A